Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Morning Review
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
    • Insider Transactions
    • Transkriptioner
  • InderesTV
  • Portfölj
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • Om oss
    • Bolag under bevakning
    • Teamet
Regulatoriskt pressmeddelande

Inside information: Modulight Corporation updates its strategy and sets new financial targets for the years 2026–2027

Modulight

Modulight Corporation | Inside Information | February 20, 2026 at 10:59:00 EET

Modulight updates its strategy and long-term financial targets, which extend until the end of the financial year 2027. The company reiterates its financial targets for revenue and EBITDA, aiming for strong annual revenue growth and a return to strong profitability. In addition, the goal is to achieve positive cash flow by the end of the strategy period. The company's dividend policy will remain unchanged.

To achieve these goals, the company plans to continue the previous strategy period with a more focused approach.

 Updated strategy period 2026–2027Previous strategy period 2023–2025
RevenueStrong annual revenue growthStrong annual revenue growth
EBITDAReturn to strong profitabilityReturn to strong profitability
Cash flowPositive cash flow-
Dividend policyAll proceeds are invested in organic and inorganic growth, and the company pays little or no dividends.All proceeds are invested in organic and inorganic growth, and the company pays little or no dividends.

Modulight’s CEO Seppo Orsila: “We made progress on many fronts during the strategy period 2023–2025. Our R&D pipeline grew and diversified from 27 to 33 projects. The most significant achievement can be considered the implementation of our new PPT business model for several customers in both ophthalmic and cancer treatments. In this business model, customers are charged for each treated patient. Our geographical expansion increased our local operations in the United States, which increased customer satisfaction. We also expanded our operations into Europe and Asia. The effectiveness of our treatment method and the validation of our technology also received several international scientific confirmations during the strategy period. In addition, we achieved carbon neutrality in our operations by consistently continuing the practices we have followed throughout the company’s 26‑year history.
Our strategy is heading in the right direction, but its implementation requires more time than we initially expected. The transition to the PPT business model, hospitals’ ability to adopt new technology, and the projects in our development pipeline have progressed more slowly. External factors have also contributed to this, but changes in geopolitics and our unique in‑house manufacturing facility in Europe have strengthened our position and future outlook. Sales grew faster in 2025 than ever before, and profitability has also begun to improve clearly during the strategy period. We are refining our strategic programs and objectives and extending the strategy implementation period by two years.”

Financial statements bulletin 4Q25 and the strategy presentation
Modulight Corporation will publish its financial statements bulletin for January–December 2025 on Friday, February 20, 2026 approximately at 11:00 a.m. EET.
Modulight's CEO Seppo Orsila will present the result and the updated strategy in an English-language webcast, which will be held on February 20, 2026, at 12:00 p.m. EET. The registration and access to the webcast are available through the following link: https://modulight.zoom.us/webinar/register/WN_sieeVYahT7CaTM4S-Crtlg
Questions can be submitted in writing through the webcast portal. CFO Anca Guina will also be present to answer questions. Presentation materials will be available before the start of the event on the company’s website at https://modulight.com/reports-presentations/.

For further information, please contact:


CEO Seppo Orsila, m. +358 40 830 4671

IR Ulla Haapanen, m. +358 40 830 4676
Email: ir@modulight.com

Certified adviser: Sisu Partners Oy, m. +358 40 555 4727
 
modulight.com
@modulight

Modulight in brief


Modulight Corporation is a life science company that designs and manufactures laser devices for the treatment of cancer and eye diseases. The company also manufactures products for other high value-add applications including flow cytometry, microscopy, semiconductor, quantum technologies, and defense. The company’s products include medical devices, subsystems, software, cloud services, and specialized semiconductors. Modulight’s products are used worldwide by many Fortune 500 companies, pharmaceutical companies, and well-known cancer centers and universities. Modulight was founded in 2000 and is headquartered in Tampere, Finland.

Follow Modulight: modulight.com | X | LinkedIn | Facebook | YouTube | Instagram | #KillCancer

Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Ta kontakt
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.